IGF-1 LR3 0.1mg × 10 vials

A synthetic long-acting IGF-1 analogue studied for growth-factor research, cellular growth pathways, muscle-tissue models, protein synthesis, glucose-metabolism mechanisms, recovery-related pathways, and anabolic signaling research protocols.

Product Overview

Compound: IGF-1 LR3
Strength: 0.1 mg / 100 mcg per vial
Injection type: Research protocol dependent
Frequency: Research protocol dependent

Reconstitution

Amount in vial: 0.1 mg / 100 mcg
BAC water: 2 mL
Amount per unit: 0.5 mcg per unit

Research Dose

Protocol dependent.

Notes

IGF-1 LR3 is described as a modified analogue of insulin-like growth factor 1 with an extended amino acid sequence and an arginine substitution at position 3. These modifications are studied for their effect on IGF-binding protein interaction and prolonged biological activity in research models.

Research literature has examined IGF-1-related pathways in relation to cellular growth, muscle-cell differentiation, protein synthesis, glucose uptake, tissue repair signaling, and anabolic regulation.

IGF-1 LR3 is not the same as standard IGF-1 and should not be treated as a consumer supplement or general wellness product.

Most available evidence comes from laboratory, animal, and limited clinical-context research. No standard consumer dosing protocol should be assumed.

Use only within appropriate research or professional guidance frameworks.